NEWS & MEDIA

Amryt Pharma – Grant of Options & Notification of…

1 December 2017

Amryt Pharma – Grant of Options & Notification of Transactions by Persons Discharging Managerial Responsibilities

Amryt announces that the Remuneration Committee has approved the grant of 2,885,582 share options (“Options“) to subscribe for ordinary shares of 1p each in the Company (“Shares“) under the Employee Share Option Plan 2016 (the “Plan“) to Joe Wiley, CEO, and Rory Nealon, CFO, details of which are set out in the table below.

The Options have an exercise price of 20.12p (“Exercise Price“). These options may be exercised as follows:

25% of the total Options granted may be exercised 12 months after the date of grant;
a further 25% of the total Options granted may be exercised 24 months after the date of grant; and
the balance of the Options may be exercised 36 months after the date of grant.

 

All Options are subject to change of control provisions and expire on the seventh anniversary of their grant.

Following the grants of these options, the following Directors have the following options:

Director

 

Options granted

 

Total Options now held

 

Joe Wiley 2,061,130 2,061,130
Rory Nealon 824,452 824,452

 

PDMR Dealings

The notification of dealing forms for each Director can be found below.  This announcement is made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014.

1.      

     

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Joe Wiley

 

2.

 

Reason for the notification

 

a) Position / status Director
b)

 

Initial notification / amendment

 

Initial notification

 

3.

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a) Name Amryt Pharma plc
b)

 

Legal entity identifier

 

213800BOS8WAJO2BEQ38

 

4.  

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the financial instrument,  type of instrument Ordinary shares of £0.01 each

 

Identification code ISIN: GB00BDD1LS57
b) Nature of the transaction Grant of pptions under the Employee Share Option Plan 2016 with an exercise price of 20.12p to purchase 2,061,130 ordinary shares.
c) Currency British Pounds
d) Price(s) and volume(s) Price(s) Volume(s)
N/A 2,061,130
e) Aggregated information

·     Aggregated volume

·     Aggregated price

 

2,061,130

N/A

f) Date of the transaction 29 November 2017
g) Place of the transaction Outside a trading venue

 

1.

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Rory Nealon

 

2.

 

Reason for the notification

 

a) Position / status Director
b)

 

Initial notification / amendment

 

Initial notification

 

3.

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a) Name Amryt Pharma plc
b)

 

Legal entity identifier

 

213800BOS8WAJO2BEQ38

 

4.

 

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a) Description of the financial instrument,  type of instrument Ordinary shares of £0.01 each

 

Identification code ISIN: GB00BDD1LS57
b) Nature of the transaction Grant of options under the Employee Share Option Plan 2016 with an exercise price of 20.12p to purchase 824,452 ordinary shares.
c) Currency British Pounds
d) Price(s) and volume(s) Price(s) Volume(s)
N/A 824,452
e) Aggregated information

·     Aggregated volume

·     Aggregated price

 

824,452

N/A

f) Date of the transaction 29 November 2017
g) Place of the transaction Outside a trading venue

 

 

 

 

Enquiries:

Amryt Pharma plc C/o KTZ Communications (details below)
Joe Wiley, CEO

Rory Nealon, CFO/COO

Shore Capital +44 (0) 20 7408 4090
Nomad and Joint Broker
Edward Mansfield, Mark Percy

 

Davy +353 (1) 679 6363
ESM Adviser and Joint Broker
John Frain, Anthony Farrell

 

Stifel +44 (0) 20 7710 7600
Joint Broker
Jonathan Senior, Ben Maddison

 

KTZ Communications +44 (0) 20 3178 6378
Katie Tzouliadis, Irene Bermont-Penn, Emma Pearson

 

About Amryt Pharma plc

(www.amrytpharma.com)

 

Amryt Pharma is a specialty biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.

 

The Company holds an exclusive licence to sell Lojuxta (lomitapide) for adults, across the European Economic Area, Middle East and North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body’s ability to remove LDL cholesterol (“bad” cholesterol) from the blood. This typically results in extremely high blood LDL cholesterol levels, leading to aggressive and premature narrowing and blocking of arterial blood vessels.  If left untreated, heart attack or sudden death may occur in childhood or early adulthood.

 

Amryt’s lead drug candidate, AP101, is a potential treatment for Epidermolysis bullosa (“EB”), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment.  It is currently in Phase 3 clinical trials. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion.

 

Amryt’s earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing’s disease.

 

The Company joined AIM and Dublin’s ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.

 

This information is provided by RNS

The company news service from the London Stock Exchange